[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.3.44. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 15, 2009

Carotid Atherosclerosis Progression and ACAT Inhibition—Reply

JAMA. 2009;302(3):255-257. doi:10.1001/jama.2009.1002

In Reply: Dr Parini and colleagues are critical that our article did not provide evidence that pactimibe inhibits ACAT-1 and ACAT-2. However, we could not specifically address this issue because the CAPTIVATE study was not designed for this purpose. Studies to assess enzyme specificity and pharmacodynamics are typically performed in earlier drug-development phases.

Parini et al suggest that we should have discussed the potential harmful effects of ACAT-1 inhibition. We did discuss that ACAT-1 inhibition might lead to accumulation of free cholesterol in macrophages, an effect that could lead to cell death. These properties suggest that ACAT-1 inhibitors are not beneficial as an antiatherosclerotic drug.

First Page Preview View Large
First page PDF preview
First page PDF preview
×